Featured Editorial
-
Blood Plasma Fractionation: Engineering And Facility Design For The Future Of Biotherapeutics
8/15/2025
This article shares key considerations for bioprocessing facility design for plasma-derived medicinal products.
-
How CZ Biohub's AI Agents Might Assist Drug Developers Beyond R&D
8/15/2025
Researchers at Stanford and the Chan Zuckerberg Biohub San Francisco developed an open-source platform of virtual researchers who talk to each other.
-
How AI Is Revolutionizing Quality Management Systems
8/13/2025
The real question isn't whether pharmaceutical companies should adopt AI in their quality systems, but how to implement it effectively and what specific benefits to expect.
-
Lean Manufacturing Implementation In Pharmaceutical Injectable Facilities
8/12/2025
This comprehensive analysis examines lean manufacturing implementation challenges and evidence-based solutions derived from leading pharmaceutical organizations.
-
July 2025 — CDMO Opportunities And Threats Report
8/11/2025
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Inside Arbor Biotech's In Vivo Gene Therapy Approach
8/6/2025
Following recent news about first-in-human testing, two executives discuss the science and manufacturing strategy for the company's lead candidate, ABO-101.
-
EMA Issues Revised Annex 11, New Annex 22, And Associated Documents On Data Governance
8/6/2025
The EMA issued three new draft documents in July, all related to the advancement of the use of electronic technology in GMP: AI, computerized systems, and documentation. The public comment period ends Oct. 7.
-
Minimizing The Impact Of Human Errors Using Relational Risk Analysis
8/4/2025
This article describes how a mechanism-based risk analysis approach can provide two complementary opportunities for minimizing the likelihood of a human error impacting pharmaceutical and medical device risks.
-
Tech Transfer 2025 – A High-Stakes Game Of Trust
8/4/2025
Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.
-
Trends And Benefits Of Lean Manufacturing In Pharmaceutical Injectable Facilities
8/4/2025
The pharmaceutical injectable manufacturing sector is experiencing unprecedented transformation through lean manufacturing adoption. This analysis examines current implementation trends, productivity impacts, and quality integration strategies based on data from leading pharmaceutical organizations.